Anthem Bioscienc Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 8 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹50.1K Cr
Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth. - Short-term quarterly growth may be lumpy, with some quarters showing exceptional performance and others moderate, but a clear upward trend is expected. - Profit margins are anticipated to remain strong, with EBITDA margins aimed at the upper end of the 36%-37% range. - The company expects growth from new commercial molecules launched recently, though ramp-up may take time as customers plan product launches. - Expansion in capacities (Unit-III and Unit-IV) will drive future revenue, with Unit-III already generating Rs.
From Anthem Bioscienc's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹871
Market Cap
₹50.1K Cr
P/E Ratio
84.5
How does Anthem Bioscienc rank in Pharmaceuticals & Biotechnology?
Compare Anthem Bioscienc against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Anthem Bioscienc — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹611 Cr, net profit ₹190 Cr.
Full financials →📊 Revenue & Sales Performance
- →Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance.
- →Recent approval of 4 new commercial molecules is expected to drive growth, though some may be in pre-launch phases affecting immediate supply volumes.
- →Quarterly revenues may be lumpy due to fluctuating customer demand, but an overall upward trend is expected annually.
- →Existing molecules are growing robustly, with customers managing inventories carefully, which may temporarily affect volumes but growth remains strong.
- →Expansion projects (Unit-III and Unit-IV) and new capacities (e.g., 130 kiloliters added recently, Unit-IV with 400 kiloliters planned) aim to support increased volumes and revenues.
- →New product launches, including peptides and biologics, and collaborations with innovators are anticipated to contribute positively over the medium term.
- →While short-term funding uncertainties exist in biotech markets, Anthem’s strong sales funnel and customer base mitigate concerns on demand.
📈 Profitability & Margins
- →Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth.
- →Short-term quarterly growth may be lumpy, with some quarters showing exceptional performance and others moderate, but a clear upward trend is expected.
- →Profit margins are anticipated to remain strong, with EBITDA margins aimed at the upper end of the 36%-37% range.
- →The company expects growth from new commercial molecules launched recently, though ramp-up may take time as customers plan product launches.
- →Expansion in capacities (Unit-III and Unit-IV) will drive future revenue, with Unit-III already generating Rs. 55 Cr WIP and expected to contribute Rs. 100-150 Cr in the near term.
- →Employee cost management and operational leverage are priorities to sustain margin expansion.
- →Overall, a healthy increase in EBITDA, PBT, PAT, and EPS is expected, aligned with revenue growth targets.
🏗️ Capital Expenditure Plans
- →Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28).
- →Unit-III: Additional Rs. 100 Cr CAPEX to complete fermentation facilities by end of current year; limited further CAPEX expected afterward.
- →Unit-II: CP 6 and CP 7 expansions (~130 KL capacity) recently commissioned with Rs. 350 Cr plus Rs. 100 Cr CAPEX done; generating revenue potential of ~Rs. 300 Cr.
- →Focus on filling existing expanded capacities (Units II & III) before ramping up Unit-IV.
- →Replacement CAPEX expected to be minor, mainly on repairs and maintenance.
- →Continuous strategic investment in people training and capacity calibration aligned with revenue growth.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →The company has ongoing capital expenditures (CAPEX) for expansions, such as Rs. 350 Cr+ Rs. 100 Cr for Unit-III and Rs. 1,000 Cr for Unit-IV, but no specific funding sources are discussed.
- →There is no explicit indication of equity or debt issuance to fund these expansions in the provided discussion.
- →The management focuses on organic growth and capacity utilization rather than discussing new fundraising rounds.
- →Any future funding plans, if considered, were not disclosed in this transcript.
📋 Order Book & Pipeline
- →Anthem Biosciences has observed a healthy inflow of new inquiries and RFPs, indicating a strong order book pipeline.
- →The company mentions being ready with capacities (including Unit-III and upcoming Unit-IV) to service new RFPs over the next 2-3 years.
- →While exact pending order numbers are not disclosed, management is enthused by the steady flow of new good customers and inquiries.
- →The commissioning of Unit-III has already started generating revenues (~Rs. 55 Cr WIP), with plans to ramp this up to Rs. 100-150 Cr, supporting order execution.
- →The upcoming Unit-IV, expected to be commissioned in about two years, will further enhance capacity to handle increased orders, reflecting confidence in sustained order inflows.
- →Overall, Anthem expects consistent order growth to maintain around 20% CAGR over the next several years based on current trends.
Key Metrics
Frequently Asked Questions
What were Anthem Bioscienc Q2 FY26 results?
Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth. - Short-term quarterly growth may be lumpy, with some quarters showing exceptional performance and others moderate, but a clear upward trend is expected. - Profit margins are anticipated to remain strong, with EBITDA margins aimed at the upper end of the 36%-37% range. - The company expects growth from new commercial molecules launched recently, though ramp-up may take time as customers plan product launches. - Expansion in capacities (Unit-III and Unit-IV) will drive future revenue, with Unit-III already generating Rs.
What is Anthem Bioscienc share price analysis?
Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anthem Bioscienc planning capital expenditure?
Unit-IV: Rs.
Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.